Nifty
:
19674.25
Sensex
:
66009.15
-68.10 (-0.34%)
-221.09 (-0.33%)
Nifty
Sensex
:
:
19674.25
66009.15
-68.10 (-0.34%)
-221.09 (-0.33%)

Sun Pharmaceutical Industries Ltd.

Pharmaceuticals & Drugs - Global

Rating :
68/99

BSE: 524715 | NSE: SUNPHARMA

NSE BSE
1146.15
21-Sep-2023
  • Open
  • High
  • Low
  • Previous Close
  •  1149.00
  •  1156.95
  •  1141.15
  •  1153.15
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2088934
  •  23976.20
  •  1169.70
  •  892.05

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 274,963.79
  • 32.67
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 275,391.38
  • 1.00%
  • 4.75

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.48%
  • 2.25%
  • 5.65%
  • FII
  • DII
  • Others
  • 16.48%
  • 18.37%
  • 2.77%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.56
  • 8.59
  • 9.42

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.12
  • 12.81
  • 6.24

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.49
  • 26.15
  • 42.97

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 38.46
  • 36.70
  • 55.74

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.87
  • 3.40
  • 3.95

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.62
  • 17.16
  • 18.78

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Dec 22
Dec 21
Var%
Sep 22
Sep 21
Var%
Net Sales
11,940.84
10,761.76
10.96%
10,930.67
9,446.76
15.71%
11,240.97
9,863.06
13.97%
10,952.28
9,625.93
13.78%
Expenses
8,611.11
8,023.04
7.33%
8,128.54
7,267.41
11.85%
8,237.25
7,256.73
13.51%
7,995.73
6,995.99
14.29%
EBITDA
3,329.73
2,738.72
21.58%
2,802.13
2,179.35
28.58%
3,003.72
2,606.33
15.25%
2,956.55
2,629.94
12.42%
EBIDTM
27.89%
25.45%
25.64%
23.07%
26.72%
26.43%
26.99%
27.32%
Other Income
206.48
147.81
39.69%
373.28
274.61
35.93%
173.88
432.51
-59.80%
85.22
222.89
-61.77%
Interest
80.88
13.69
490.80%
92.74
37.34
148.37%
46.18
18.97
143.44%
19.39
35.95
-46.06%
Depreciation
651.32
588.00
10.77%
671.53
556.47
20.68%
659.95
553.68
19.19%
609.95
530.37
15.00%
PBT
2,481.14
2,284.84
8.59%
2,239.69
-2,075.60
-
2,471.47
2,466.19
0.21%
2,412.43
2,286.51
5.51%
Tax
468.10
188.99
147.69%
222.91
146.76
51.89%
283.43
335.39
-15.49%
152.26
197.78
-23.02%
PAT
2,013.04
2,095.85
-3.95%
2,016.78
-2,222.36
-
2,188.04
2,130.80
2.69%
2,260.17
2,088.73
8.21%
PATM
16.86%
19.48%
18.45%
-23.53%
19.46%
21.60%
20.64%
21.70%
EPS
8.43
8.59
-1.86%
8.27
-9.49
-
9.03
8.58
5.24%
9.43
8.53
10.55%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
45,064.76
43,885.68
38,654.49
33,498.14
32,837.50
29,065.91
26,415.54
31,308.14
28,108.61
27,392.01
16,080.36
Net Sales Growth
13.52%
13.53%
15.39%
2.01%
12.98%
10.03%
-15.63%
11.38%
2.62%
70.34%
 
Cost Of Goods Sold
10,520.13
10,662.16
10,351.54
8,690.08
9,230.45
7,868.97
7,351.71
8,164.20
6,170.19
6,732.84
2,777.68
Gross Profit
34,544.63
33,223.52
28,302.95
24,808.06
23,607.05
21,196.94
19,063.83
23,143.94
21,938.42
20,659.17
13,302.68
GP Margin
76.66%
75.70%
73.22%
74.06%
71.89%
72.93%
72.17%
73.92%
78.05%
75.42%
82.73%
Total Expenditure
32,972.63
32,424.22
28,772.68
25,030.42
25,863.35
22,792.27
20,880.73
21,625.92
19,950.29
19,615.54
9,120.95
Power & Fuel Cost
-
830.05
702.78
627.09
621.89
613.60
559.97
525.09
545.44
560.77
232.41
% Of Sales
-
1.89%
1.82%
1.87%
1.89%
2.11%
2.12%
1.68%
1.94%
2.05%
1.45%
Employee Cost
-
8,296.03
7,300.83
6,862.23
6,362.35
5,967.09
5,367.05
4,902.30
4,772.31
4,502.64
2,074.44
% Of Sales
-
18.90%
18.89%
20.49%
19.38%
20.53%
20.32%
15.66%
16.98%
16.44%
12.90%
Manufacturing Exp.
-
1,936.77
1,880.71
1,723.78
1,690.00
1,884.71
1,827.40
1,293.98
1,418.59
1,433.89
815.49
% Of Sales
-
4.41%
4.87%
5.15%
5.15%
6.48%
6.92%
4.13%
5.05%
5.23%
5.07%
General & Admin Exp.
-
4,256.12
3,270.55
3,179.45
3,340.89
2,729.20
2,862.45
3,113.67
2,956.85
2,894.97
978.48
% Of Sales
-
9.70%
8.46%
9.49%
10.17%
9.39%
10.84%
9.95%
10.52%
10.57%
6.08%
Selling & Distn. Exp.
-
5,226.24
4,096.33
3,103.96
3,654.48
2,621.13
1,864.55
2,520.64
2,262.35
2,236.40
1,394.78
% Of Sales
-
11.91%
10.60%
9.27%
11.13%
9.02%
7.06%
8.05%
8.05%
8.16%
8.67%
Miscellaneous Exp.
-
1,216.85
1,169.94
843.83
963.29
1,107.57
1,047.60
1,106.04
1,824.56
1,254.03
1,394.78
% Of Sales
-
2.77%
3.03%
2.52%
2.93%
3.81%
3.97%
3.53%
6.49%
4.58%
5.27%
EBITDA
12,092.13
11,461.46
9,881.81
8,467.72
6,974.15
6,273.64
5,534.81
9,682.22
8,158.32
7,776.47
6,959.41
EBITDA Margin
26.83%
26.12%
25.56%
25.28%
21.24%
21.58%
20.95%
30.93%
29.02%
28.39%
43.28%
Other Income
838.86
819.85
1,437.42
859.17
651.59
1,059.44
912.08
1,030.20
658.25
637.89
592.59
Interest
239.19
172.00
127.35
141.43
302.73
555.25
517.57
399.80
523.24
578.99
44.19
Depreciation
2,592.75
2,529.43
2,143.74
2,079.95
2,052.78
1,753.25
1,499.84
1,264.75
1,037.53
1,194.72
409.23
PBT
9,604.73
9,579.88
9,048.14
7,105.51
5,270.23
5,024.58
4,429.48
9,047.87
7,255.80
6,640.65
7,098.58
Tax
1,126.70
847.59
1,075.50
514.69
822.80
600.88
911.04
1,211.57
913.77
914.69
702.17
Tax Rate
11.73%
9.01%
24.00%
18.39%
16.42%
15.77%
26.19%
13.39%
13.91%
14.29%
15.33%
PAT
8,478.03
8,521.48
3,289.27
2,916.15
3,779.76
2,666.88
2,121.14
6,954.44
4,544.26
4,551.94
3,141.47
PAT before Minority Interest
8,488.07
8,560.84
3,405.82
2,284.68
4,186.79
3,209.32
2,567.94
7,836.30
5,656.86
5,488.21
3,879.00
Minority Interest
10.04
-39.36
-116.55
631.47
-407.03
-542.44
-446.80
-881.86
-1,112.60
-936.27
-737.53
PAT Margin
18.81%
19.42%
8.51%
8.71%
11.51%
9.18%
8.03%
22.21%
16.17%
16.62%
19.54%
PAT Growth
107.13%
159.07%
12.79%
-22.85%
41.73%
25.73%
-69.50%
53.04%
-0.17%
44.90%
 
EPS
35.34
35.52
13.71
12.15
15.75
11.12
8.84
28.99
18.94
18.97
13.09

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
55,995.38
48,011.22
46,462.78
45,264.45
41,409.06
38,314.11
36,639.67
32,982.48
25,638.09
18,524.95
Share Capital
239.93
239.93
239.93
239.93
239.93
239.93
239.93
240.66
207.12
207.12
Total Reserves
55,755.45
47,771.29
46,222.85
45,024.52
41,169.13
38,074.18
36,397.10
32,736.26
25,374.38
18,317.83
Non-Current Liabilities
-1,643.12
-1,316.37
-1,515.17
246.05
76.72
46.43
599.87
2,169.59
2,335.46
1,748.41
Secured Loans
0.00
0.00
7.83
6.18
109.47
217.69
185.59
7.73
40.69
43.76
Unsecured Loans
0.00
229.92
646.88
2,022.74
1,413.14
1,554.40
1,250.49
3,102.57
1,327.73
4.91
Long Term Provisions
342.91
369.07
327.12
511.00
430.39
404.46
1,211.11
1,895.86
2,532.34
2,601.62
Current Liabilities
19,906.38
17,208.45
16,145.63
15,706.43
17,339.62
19,864.32
17,887.02
13,143.96
16,146.81
5,989.59
Trade Payables
5,681.52
4,489.76
3,973.66
3,583.64
4,147.87
4,766.20
4,395.39
3,582.92
3,286.54
1,328.26
Other Current Liabilities
2,603.51
2,926.73
4,965.34
2,535.02
1,761.72
1,875.93
2,673.68
1,134.27
2,279.59
260.41
Short Term Borrowings
5,958.26
468.52
2,444.90
5,549.38
8,370.76
7,979.70
6,654.92
5,206.12
6,227.92
2,440.34
Short Term Provisions
5,663.09
9,323.44
4,761.73
4,038.39
3,059.27
5,242.49
4,163.03
3,220.65
4,352.76
1,960.58
Total Liabilities
77,578.73
66,958.19
64,110.29
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
Net Block
24,420.12
22,665.16
21,552.98
22,846.91
21,836.54
18,852.65
17,675.17
15,872.25
12,682.47
6,817.28
Gross Block
43,454.63
38,707.36
35,578.99
35,115.97
31,687.04
26,948.80
24,466.42
22,180.41
20,406.89
10,485.12
Accumulated Depreciation
19,034.51
16,042.20
14,026.01
12,269.06
9,850.50
8,096.15
6,791.25
6,308.16
7,724.42
3,667.84
Non Current Assets
37,696.01
32,093.59
33,668.21
33,423.01
31,069.75
30,473.12
25,963.77
22,439.98
18,055.80
9,497.56
Capital Work in Progress
4,973.16
1,286.80
1,566.83
1,220.34
1,411.15
2,465.16
2,801.38
2,175.45
2,038.61
841.54
Non Current Investment
5,457.48
5,214.65
6,482.39
5,245.75
3,951.81
3,052.25
961.00
1,116.07
598.87
787.56
Long Term Loans & Adv.
2,752.12
2,880.86
4,061.34
4,104.48
3,848.29
6,052.85
3,844.04
2,322.87
2,631.91
1,016.98
Other Non Current Assets
93.13
46.12
4.67
5.53
21.96
50.21
682.18
953.34
103.94
34.20
Current Assets
39,861.94
34,864.60
30,442.08
31,654.16
31,069.19
31,635.90
32,953.65
29,941.30
28,915.75
18,686.46
Current Investments
9,372.61
7,633.94
3,130.06
4,897.36
3,950.72
4,090.62
230.88
713.81
2,117.43
1,998.46
Inventories
10,513.05
8,925.13
8,997.02
7,874.99
7,885.98
6,880.69
6,832.81
6,422.54
5,667.99
3,123.01
Sundry Debtors
11,438.51
10,484.59
9,061.40
9,421.24
8,884.20
7,815.28
7,202.61
6,775.66
5,106.13
2,200.42
Cash & Bank
5,770.29
5,033.35
6,445.51
6,487.55
7,275.60
9,929.38
15,140.84
13,181.65
10,998.04
7,590.15
Other Current Assets
2,767.48
775.01
1,319.11
1,541.48
3,072.69
2,919.93
3,546.51
2,847.64
5,026.16
3,774.42
Short Term Loans & Adv.
2,021.57
2,012.58
1,488.98
1,431.54
1,806.39
2,028.62
2,828.26
2,317.13
1,920.52
1,093.74
Net Current Assets
19,955.56
17,656.15
14,296.45
15,947.73
13,729.57
11,771.58
15,066.63
16,797.34
12,768.94
12,696.87
Total Assets
77,557.95
66,958.19
64,110.29
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
4,959.33
8,984.54
6,170.37
6,554.77
2,196.45
3,907.15
7,082.21
6,685.86
5,615.74
3,959.20
PBT
9,408.43
4,481.32
2,799.37
5,009.59
3,810.20
3,478.98
9,047.87
6,570.63
6,402.90
4,581.17
Adjustment
2,722.56
1,974.95
1,809.85
1,992.54
1,968.66
1,382.22
500.67
1,856.92
773.61
-40.15
Changes in Working Capital
-5,661.82
1,559.05
2,564.09
898.55
-2,696.00
-212.31
-409.21
246.77
179.59
207.10
Cash after chg. in Working capital
6,469.17
8,015.32
7,173.31
7,900.68
3,082.86
4,648.89
9,139.33
8,674.32
7,356.10
4,748.12
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,509.84
969.22
-1,002.94
-1,345.91
-886.41
-741.74
-2,057.12
-1,988.46
-1,740.36
-788.92
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-7,943.68
-5,724.74
536.22
-2,588.84
-681.25
-3,370.81
-4,221.60
-4,371.59
-2,865.74
-2,366.76
Net Fixed Assets
-573.97
-1,120.95
-8,061.35
-737.44
-543.38
-1,471.92
-1,217.15
2,214.23
-4,631.67
-380.81
Net Investments
2,932.47
-11.67
1,824.52
542.39
451.15
978.04
3,038.39
3,504.47
-18,860.43
-2,698.19
Others
-10,302.18
-4,592.12
6,773.05
-2,393.79
-589.02
-2,876.93
-6,042.84
-10,090.29
20,626.36
712.24
Cash from Financing Activity
2,376.07
-5,193.46
-5,980.48
-5,715.14
-2,730.52
-1,539.26
-2,285.39
-1,888.53
-1,186.53
506.57
Net Cash Inflow / Outflow
-608.28
-1,933.66
726.11
-1,749.21
-1,215.32
-1,002.92
575.22
425.74
1,563.47
2,099.01
Opening Cash & Equivalents
4,508.25
6,273.03
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69
7,183.49
4,358.70
2,069.11
Closing Cash & Equivalent
4,623.73
4,508.25
6,273.03
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69
7,285.56
4,358.70

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
233.38
200.11
193.65
188.66
172.59
159.69
152.70
137.03
123.49
89.44
ROA
11.85%
5.20%
3.54%
6.58%
5.17%
4.24%
0.00%
11.39%
14.60%
16.21%
ROE
16.46%
7.21%
4.98%
9.66%
8.05%
6.85%
0.00%
19.32%
24.89%
23.15%
ROCE
17.24%
9.28%
5.68%
10.07%
8.68%
8.40%
0.00%
18.64%
25.06%
25.46%
Fixed Asset Turnover
1.81
1.81
1.74
1.78
1.92
1.99
1.29
1.34
1.79
1.70
Receivable days
53.89
53.09
54.88
56.22
54.10
53.53
83.25
76.12
48.20
51.72
Inventory Days
47.78
48.68
50.10
48.40
47.84
48.88
78.98
77.46
57.99
63.92
Payable days
174.10
149.21
158.71
152.86
77.81
90.19
85.47
75.24
52.05
56.33
Cash Conversion Cycle
-72.43
-47.44
-53.73
-48.24
24.13
12.23
76.75
78.34
54.14
59.31
Total Debt/Equity
0.11
0.02
0.08
0.18
0.25
0.27
0.27
0.26
0.35
0.14
Interest Cover
55.70
36.19
20.79
17.55
7.86
7.72
23.63
13.56
12.06
104.67

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014

News Update:


  • Sun Pharmaceutical’s arm enters into license agreement with Pharmazz Inc
    14th Sep 2023, 11:40 AM

    The company has entered into license agreement to commercialise a first-in-class innovative drug, Tyvalzi (Sovateltide) in India

    Read More
  • Sun Pharma aiming to spend 7-8% of sales on R&D in current fiscal
    29th Aug 2023, 11:27 AM

    The Mumbai-based drug major spent about Rs 2,400 crore on R&D in 2022-23

    Read More
  • Sun Pharmaceutical Industries reports marginal fall in Q1 consolidated net profit
    3rd Aug 2023, 14:28 PM

    Total consolidated income of the company increased by 12.83% at Rs 12145.28 crore for Q1FY24

    Read More
  • Sun Pharma Inds. - Quarterly Results
    3rd Aug 2023, 14:05 PM

    Read More
  • Sun Pharma eyeing at high single-digit growth in consolidated topline in FY24
    31st Jul 2023, 15:09 PM

    The Mumbai-based company had reported a consolidated revenue of Rs 43,278 crore in 2022-23

    Read More
  • Sun Pharmaceutical Industries’ arm gets Health Canada’s nod for WINLEVI
    20th Jun 2023, 10:22 AM

    WINLEVI will be available in Canada this fall

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.